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The Glu318Gly Substitution in Presenilin 1 Is Not
Causally Related to Alzheimer Disease
To the Editor:
With 49 different mutations in the coding region, pre-
senilin 1 (the gene is denoted “PSEN1”; the protein is
denoted “psen1”) is the most frequently mutated gene
in early onset (onset age !65 years) Alzheimer disease
(AD [MIM 104300]) (Sherrington et al. 1995; Cruts and
Van Broeckhoven 1998). PSEN1 missense mutations are
generally considered fully penetrant mutations. Mostly
they are found in patients with a positive family history
of early-onset AD compatible with autosomal dominant
inheritance. Patients carrying the same mutation usually
display very similar onset ages (Van Broeckhoven 1995).
An ArG transition at codon 318 in exon 9 of PSEN1,
resulting in the nonconserved GlurGly substitution, has
been reported, by us (Cruts et al. 1998) and others
(Sandbrink et al. 1996; Forsell et al. 1997), in familial
AD cases with onset ages of 35–64 years (Cruts and Van
Broeckhoven1998). However, segregation of Glu318Gly
with AD could not be demonstrated, because either no
or too few relatives were available for DNA testing.
PSEN1 Glu318Gly involves the last codon of exon 9
and is located in the middle part of the sixth hydrophilic
loop of psen1. Because of the high variability in onset
age of AD and the mutation’s location in a psen1 region
that is less conserved between psen homologues in hu-
man and other species, we previously had hypothesized
that the Glu318Gly could be either an incompletely pen-
etrant mutation or a rare polymorphism (Cruts and Van
Broeckhoven 1998).
To evaluate the frequency of Glu318Gly and its con-
tribution to AD, we screened incident and prevalent de-
mented cases and age- and sex-matched controls derived
from the Rotterdam Study. This is a prospective single-
center population-based study of elderly residents 55
years of age who are from a Rotterdam suburb (Hofman
et al. 1991). Cognitive functioning was assessed and di-
agnosis of dementia made on the basis of the DSM-III-
R definition (American Psychiatric Association 1987).
Possible and probable AD was diagnosed according to
the National Institute of Neurological and Communi-
cative Disorders and Stroke (NINCDS)–Alzheimer’s
Disease and Related Disorders Associations criteria
(McKhann et al. 1984). Vascular dementia was diag-
nosed according to NINCDS–Association Internationale
pour la Recherche et l’Enseignement en Neurosciences
criteria (Roman et al. 1993). At baseline, 474 prevalent
demented cases were diagnosed (Ott et al. 1995). During
follow-up, another 146 incident cases of dementia were
detected (Ott et al. 1998). From 345 prevalent cases,
134 incident cases, and 256 controls, blood samples
were available for DNA extraction. Controls were ran-
domly selected among nondemented participants in the
Rotterdam Study and were group matched on the basis
of age (5-year intervals) and sex. To facilitate rapid
screening for Glu318Gly, we developed a mismatch PCR
assay that allows detection by BstNI digestion of the
mismatch PCR product. The forward mismatched
primer was 5′-ATCCAAAAATTCCAAGTATAATCC-
AG-3′ and the reverse primer was 5′-CTGGGCAT-
TATCATAGTTCTCAAG-3′.
PSEN1 Glu318Gly was observed in 2 (1.5%) incident
and 11 (3.4%) prevalent demented cases and in 9 (4.1%)
controls. In contrast to previous reports, we detected
Glu318Gly in individuals who were elderly. The fre-
quencies in incident and prevalent cases versus those in
controls were compared by the Fisher exact test and were
found to be not significantly different ( andP  .22
, respectively). Of 13 demented Glu318Gly car-P  .65
riers, 10 were diagnosed with AD (4 possible AD and
6 probable AD), 1 with dementia associated with Par-
kinson disease, 1 with vascular dementia, and 1 with
dementia associated with multiple sclerosis. Mean age
at onset in demented Glu318Gly carriers (83.4 4.7
years, range 72–88 years) was similar to that in de-
mented noncarriers ( years, range 52–9781.0 7.7
years). Cognitive functioning measured by the mini-men-
tal state examination in the control group was similar
in Glu318Gly carriers ( ) and noncarriers26.4 2.9
( ). Since the e4 allele of apolipoprotein E27.0 2.0
(APOE) is known to increase risk for AD (Pericak-Vance
and Haines 1995), we also examined the APOE geno-
types in the demented cases. However, the APOE*e4-
allele frequency in the demented Glu318Gly cases (19%)
was not different from that in the total group of de-
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mented cases (21%), excluding a possible interaction
between APOE*e4 and Glu318Gly. Together, these find-
ings demonstrate that Glu318Gly is a rare allele (22
carriers/676 individuals, allele frequency 1.6%) in the
Dutch population analyzed and that its presence is not
associated with AD or dementia in general.
The relatively high frequency of Glu318Gly in the
Dutch population analyzed may be explained if all sub-
jects are distantly related. To test this possibility, we
genotyped several polymorphic DNA markers located
within and near PSEN1 (Cruts et al. 1995, 1998). All
Glu318Gly carriers (cases and controls) shared one allele
for D14S77 (203 bp; frequency 8%), the PSEN1 pro-
moter (allele T; frequency 12%), and intron 8 poly-
morphisms (allele A; frequency 54%). Allele sharing was
also observed at D14S1028, with 20 of 22 Glu318Gly
carriers sharing the same allele (239 bp; frequency 4%).
No obvious sharing of alleles was observed at
D14S1004. Frequencies of the shared alleles were cal-
culated in 118 control individuals coming from the same
Rotterdam suburb (C. M. van Duijn, unpublished data).
The probability of detecting this allele combination in-
dependently in 22 cases ( ) strongly suggests354# 10
that all Dutch Glu318Gly carriers have one common
founder. Glu318Gly is also frequently observed in pop-
ulations of different geographic and ethnic origins
(Baker et al. 1998; Forsell et al. 1998; Helisalmi et al.
1998; Mattila et al. 1998; Reznik-Wolf et al. 1998; Tor-
res et al. 1998).
The mechanism by which mutations in PSEN1 lead
to AD remains largely unknown. However, an increasing
amount of in vivo and in vitro evidence suggests that
the mutated psen1 expresses its pathogenic effect by pro-
cessing the amyloid precursor protein (APP) in such a
way that increased levels of the 42-amino-acid form of
the amyloid b peptide (Ab42) are secreted (Hardy 1997).
Ab42 is believed to be pathogenic, since it is more prone
to aggregation and therefore leads to accelerated amy-
loid b accumulation in the brain of patients with AD.
To assess whether Glu318Gly also influences APP pro-
cessing, we measured Ab42 levels in conditioned media
of HEK-293 cells stably transfected with the Glu318Gly
PSEN1 cDNA, using an Ab42-specific enzyme-linked
immunosorbent assay (De Strooper et al. 1998). No in-
crease in Ab42 secretion was observed, compared with
cell lines stably transfected with wild-type PSEN1
cDNA. The absence of increased APP processing into
Ab42 in vitro is consistent with our findings at the pop-
ulation level, which show no association of Glu318Gly
with either AD or dementia.
A few possibilities remain unexplored. First, since we
detected the Glu318Gly allele only in the heterozygous
state, it cannot be excluded that Glu318Gly is associated
with dementia in an autosomal recessive manner. How-
ever, there is no evidence supporting autosomal recessive
inheritance in familial AD (Rao et al. 1994). The fact
that neither none of 479 late-onset patients screened in
the present study nor the 100 early-onset cases screened
in earlier studies (Cruts et al. 1998) carried two copies
of the allele makes it unlikely that homozygosity for
Glu318Gly is a frequent cause of AD. Another as yet
not excluded possibility is that all Glu318Gly carriers
share a (disease) phenotype that is different from either
AD or dementia and that has remained undetected in
the present study. However, we are not aware of any
nondementia phenotypes associated with genetic varia-
tions in PSEN1.
In conclusion, we provide evidence that PSEN1
Glu318Gly is not causally related to either AD or other
types of dementia. The latter has important implications
for genetic counseling, since Glu318Gly carriers are not
at increased risk. Our observations also imply that care
should be taken in assigning a pathological nature to
mutations in PSEN1, when these mutations are reported
in isolated cases or in familial cases but in the absence
of conclusive evidence for cosegregation with the disease.
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